Pipeline

The MMRC and its team of Principal Investigators are committed to excellence in multiple myeloma research. With lives on the line, everything we do focuses on accelerating discovery and rapidly advancing medicine.

Active Clinical Trials


Title Description Phase Link
No Novel SMM trials at this time.

Title Description Phase Link
Revlimid/Dexamethasone/Empliciti +/- Cytoxan (Amyloidosis) This trial for patients with primary amyloidosis examines how well Empliciti, Revlimid, and Dex (ERd) work with or without Cytoxan Phase 2 Click here

Title Description Phase Link
Kyprolis/Jakafi This study looks at efficacy of a combination of Kyprolis (a PI) and Jakafi (a JAK kinase inhibitor)with Dex in RRMM. Phase1/2 Click here
Selinexor/Kyprolis A phase 1 study of combination of a Selective Inhibitor of Nuclear Export (SINE) with Kyprolis and Dex in patients with RRMM. Phase 1 Click here

Title Description Phase Link
No Antibodies & Immune SMM trials at this time.

Title Description Phase Link
Darzalex Subcutaneous This trial for post-ASCT myeloma tests how well Darzalex works by injection under the skin (subcutaneous) vs intravenous (IV) injection. Phase 2 Click here
Darzalex- SCT: A Phase II study of Darzalex as a consolidation/maintenance therapy after an ASCT. Darzalex is now being studied as a more convenient form of delivery, in injection formulation. Phase 2 Click here
Darzalex/Kyprolis/Revlimid/Dex This study aims to evaluate the effectiveness of Darzalex with Kyprolis, Revlimid and Dex (Dara-KRd) combination in NDMM. Phase 2 Click here

Title Description Phase Link
Isatuximab/Kyprolis This study looks at the safety of Isatuximab + Kyprolis in RRMM patients who have received at least two prior therapeutic treatments or regimens. Once a safe dose is established, an expansion cohort will further evaluate safety and begin to assess activity of this combo. Phase 1b Click here
Empliciti/Pomalyst/Dex/ 2nd Transplant A phase II study of Empliciti, Pomalyst and Dexamethasone (Elo-Pom-Dex) with a second ASCT for RRMM patients. Phase 2 Click here
Pomalyst/Dex/Kyprolis This study of safety and tolerability of Pomalyst, dexamethasone, and Kyprolis (PKd) in patients with Relapsed MM. Phase 1b Click here
B-RAF/MEK RAS/RAF mutations BRAF, KRAS, or NRAS gene mutations. Prior research of Dabrafenib and Trametinib has suggested that these agents may help kill myeloma cells. Open label Pilot Click here
PINR Biomarker-driven: Goal is to look at Ninlaro/Dex (Nd) or Ninlaro/Dex + Revlimid (NRd) and how well these combos work based on the rearrangement of a gene called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NFKB2) in treating RRMM patients. Phase 2 Click here
Darzalex Single agent This Phase II study is to determine if Darzalex will improve the rate of prevention of MM. Phase 2 Click here
Empliciti/Kyprolis/Revlimid/Dex This study for NDMM patients will evalute the combo of Empliciti + Kyprolis, Revlimid and Dex (E-KRd) in NDMM patients. A calculated measure of the study will be the rate of MRD by next generation gene sequencing (NGS). Phase 2 Click here
Ninlaro/Revlimid/Dex SCT Trial for MM patients who have residual disease after donor stem cell transplant. This trial studies how well Revlimid alone works compared to a combo of Revlimid, Ninlaro and Dex (NRd regimen). Phase 2 Click here

Title Description Phase Link
No PI's & IMID's SMM trials at this time.

Title Description Phase Link
No PI's & IMID's New DX./Transplant trials at this time.

Title Description Phase Link
Pomalyst/Ninlaro EMD/PCL (PI's and IMiDs) A study looks at the efficacy of Pomalyst, Ninlaro and Dex (NPd) in treating patients with previously treated MM or plasma cell leukemia. Phase 2 Click here

Title Description Phase Link
No Molecularly Targeted SMM trials at this time.

Title Description Phase Link
No Molecularly Targeted New DX./Transplant trials at this time.

Title Description Phase Link
MDM2i/Ixa 17p deleted (molecularly targeted) A molecularly targeted study for patients who have been diagnosed with a deletion 17p (del17p) or monosomy 17 with RRMM. This study uses Pomalyst-Ninlaro-Dex (NPd) to stop the growth of cancer cells. Phase 1/2 Click here
MyDRUG: The first ever Platform Trial for patients with High Risk MM. A molecularly targeted study, patients are placed on a treatment based on their unique mutations and alterations in myeloma cells. Treatment varies and is based on their genetic sequencing results. This is a leap towards targeted therapy. Phase 1/2 Click here

The MMRC has conducted nearly 100 Phase I and II trials enrolling more than 1,700 patients to-date, providing invaluable insight into the successful conduct of multiple myeloma clinical trials.

The major differentiating factors in working with MMRC for the conduct of Phase I and II trials in multiple myeloma are:

  • Streamlined communication—single point of contact who can leverage MMRC’s extensive MM Phase I/II clinical trial experience
  • MMRC is a recognized MM center of excellence for Phase I/II trials with focus on quality of trial conduct and data integrity, including renowned MM Key Opinion Leaders (KOL)
  • Leveraging a patient-driven collaborative research model that demonstrates faster trial starts and enrollment for MM Phase I/II trials

Search Current Clinical Trials